secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001104659-25-045557
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q1 revenue $41M, up 10% YoY; cell & gene therapy revenue up 33%
------------------------------------------------------------------------

- Commercial Cell & Gene therapy revenue $7.2M, up 33% YoY; supported 19 commercial therapies.
- Life Sciences Services revenue $22.9M (+17%); Products $18.2M (+2%); total continuing ops $41.0M.
- Strategic DHL partnership; CRYOPDP divestiture expected Q2/Q3 2025, providing capital infusion.
- Supported 711 global clinical trials (net +36 YoY); 79 Phase 3; six BLA/MAA filings in Q1.
- Abeona's ZEVASKYN FDA-approved post-Q1; 17 more application filings anticipated in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465925045557/0001104659-25-045557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465925045557/tm2514334d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer